Sponsored Links
| Ironwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome With Constipation |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with irritable bowel syndrome with constipation (IBS-C) during the 2011 Digestive Disease Week (DDW) annual meeting that will be held in Chicago from May 7 through May 10, 2011... Read more: Irritable-Bowel Syndrome News From Medical News Today
|